Printer Friendly

ANTIBIOTICS LICENSED TO WYETH-AYERST

 ANTIBIOTICS LICENSED TO WYETH-AYERST
 PHILADELPHIA, Aug. 31 /PRNewswire/ -- Wyeth-Ayerst Laboratories, a


division of American Home Products Corporation (NYSE: AHP) announced today that American Home Products and Suntory Ltd., of Osaka, Japan, had entered into an agreement for penem antibiotics with a broad antibacterial spectrum against aerobic and anaerobic bacteria.
 The oral form of this product is expected to be the first oral penem to reach the U.S. market. Penems are beta-lactams similar in structure to the penicillins whose bactericidal activity is the result of binding to the penicillin-binding proteins and thereby stopping cell wall synthesis. In addition to having a broader spectrum of activity than the penicillins, the penems are stable to beta-lactamases, the enzymes that degrade penicillins.
 Under the terms of the agreement, Wyeth-Ayerst received the exclusive rights to develop and commercialize the oral and injectable forms of these compounds in North, Central and South America. The antibiotics are intended for the treatment of mild to severe bacterial infections; Phase III clinical trials of an oral formulation are in progress in Japan. Wyeth-Ayerst will be filing an IND in the United States for the compounds.
 Stated Robert I. Levy, M.D., president of Wyeth-Ayerst Research, "We are enthusiastic about our new relationship with Suntory Ltd. It represents another important step in our strategy to engage in collaborative agreements to extend and complement our own research capabilities and discovery base."
 Wyeth-Ayerst, a division of American Home Products Corporation, is a major research-oriented pharmaceutical company with leading products in the areas of female health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines and infant nutritionals. American Home Products Corporation is a worldwide manufacturer and marketer of prescription drugs, medical supplies and diagnostic equipment, over-the-counter medicines and food products.
 Suntory, a world leader in the production and marketing of fine spirits, wines, beer and other beverages, entered the pharmaceutical field in 1979. Suntory launched its first product, the anti-arrhythmic, Sunrythm(R), in 1991.
 /delval/
 -0- 8/31/92
 /CONTACT: Audrey Ashby of Wyeth-Ayerst Laboratories, 215-971-5823/
 (AHP) CO: Wyeth-Ayerst Laboratories; American Home Products Corporation;
 Suntory Ltd. ST: Pennsylvania IN: MTC SU: PDT


MP-LJ -- PH004 -- 4830 08/31/92 09:19 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1992
Words:364
Previous Article:AMERICAN FUNERAL SERVICES CORPORATION REPORTS OFFER BY SERVICE CORPORATION
Next Article:ANALOG DEVICES DENIES PUBLISHED REPORT THAT SAYS COMPANY PLANNING SUBMICRON WAFER FAB WITH FUJITSU
Topics:


Related Articles
SEARLE AND WYETH-AYERST CO-PROMOTE ONLY ONCE-A-DAY QUINOLONE ANTIBIOTIC
FDA CLEARS ZOSYN FOR NOSOCOMIAL PNEUMONIA
ChemGenics and American Home Products Announce Collaboration in Antibacterial Drug Discovery
Lederle Files With FDA, Seeking Licensure for Use of Combination DTAP-Hib Vaccine in Children
CoCensys Licenses Novel Anxiety Treatment to Wyeth-Ayerst
Genset Enters Into a Chlamydiae Vaccine License Agreement with American Home Products Corporation
Wyeth-Ayerst Receives FDA Licensure for RotaShield; First Vaccine for Use in the Prevention of Rotavirus
Elan Renews Collaboration in Integrin Field with American Home Products Corporation.
CAT Enters Into Product Development Agreement With Wyeth Research Relating to Alzheimer's Amyloid Beta Target.
American Home Products and Aventis Pharma Reach New Agreement for Development and Marketing of Trimegestone.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters